XENOGEN CORP
S-1/A, EX-23.1, 2001-01-19
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: XENOGEN CORP, S-1/A, 2001-01-19
Next: XENOGEN CORP, 8-A12G, 2001-01-19



<PAGE>

                                                                    Exhibit 23.1

               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

We consent to the references to our Firm under the caption "Experts" and to the
use of our report dated February 4, 2000 (except for Notes 1 and 12, for which
the date is       , 2001), in Amendment No. 4 to the Registration Statement on
Form S-1 (No. 333-47030) and related Prospectus of Xenogen Corporation for the
registration of 7,000,000 shares of its common stock.

Palo Alto, California

The foregoing consent is in the form that will be signed upon the completion of
the 0.73-for-one reverse stock split described in Notes 1 and 12 to the
financial statements.

                                          /s/ Ernst & Young LLP

Palo Alto, California

January 18, 2001

We consent to the references to our Firm under the caption "Experts" in
Amendment No. 4 to the Registration Statement on Form S-1 (No. 333-47030) and
related Prospectus of Xenogen Corporation and to the use of our report dated
September 15, 2000 on the financial statements of Chrysalis DNX Transgenic
Sciences Corporation, included in Amendment No. 4 to the Registration Statement
on Form S-1 (No. 333-47030) and related Prospectus of Xenogen Corporation for
the registration of 7,000,000 shares of its common stock.

                                          /s/ Ernst & Young LLP

MetroPark, New Jersey

January 18, 2001

--------------------------------------------------------------------------------


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission